Trial · NCT04742504
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fold changes in number of basophils | From 1 to 12 months | Fold changes in number of basophils after 8 week, 6 months and 1 year of benralizumab treatment (Fasenra®, Astra Zeneca) in blood and sputum in patients with severe eosinophilic asthma |
| Primary | Fold changes in number of innate inmmune cells | From 1 to 12 months | Fold changes in number of innate immune cells s after 8 week, 6 months and 1 year of benralizumab treatment (Fasenra®, Astra Zeneca) in blood and sputum in patients with severe eosinophilic asthma |
| Primary | The fold changes of IL-5R expression in basophils | From 1 to 12 months | The fold changes of IL-5R expression in basophils after 8 week, 6 months and 1 year of benralizumab treatmen |
| Primary | The fold changes of f IL-5R expression in innate lymphoid cells | From 1 to 12 months | The fold changes of f IL-5R expression in innate lymphoid cells after 8 week, 6 months and 1 year of benralizumab treatment |
| Secondary | Fold changes of miRNAs profile in basophils | From 6 to 18 | 1\. Fold changes of miRNAs profile in basophils after tratment of Benralizumab in in patients with severe eosinophilic asthma treatment. |
| Secondary | Fold changes of serum IL-5R | Fromm 6 to 12 | Fold changes of serum IL-5R (microg/ml) in patients treated with benralizumab |
| Secondary | Effect of benralizumab in basophil apoptosis | From 12 to 24 months | The effect of benralizumab in basophil apoptosis isolated from from allergic asthmatic patients will be measure by fold change of annexin V |
| Secondary | Effect of benralizumab in KU812 apoptosis | From 12 to 24 months | The effect of benralizumab in KU812 apoptosis will be measure by fold change of annexin V in KU812 cultures |
| Secondary | Effect of benralizumab in basophil activation | From 12 to 24 months | The effect of benralizumab in basophil activation isolated from from allergic asthmatic patients will be measur by fold change of CD63, and CD203C on membrane by flow cytometry |
| Secondary | Effect of benralizumab in KU812 activation | From 12 to 24 months | The effect of benralizumab in KU812 activation will be measurie by fold change of CD63, and CD203C on membrane by flow cytometry |
| Secondary | Effect of benralizumab in basophil degranulation | From 12 to 24 months | The effect of benralizumab in basophil degranulation will be measure by histamine releasing in isolated basophils from from allergic asthmatic patients |
| Secondary | Effect of benralizumab in KU812 degranulation | From 12 to 24 months | The effect of benralizumab in basophil degranulation will be measure by histamine releasing in KU812 cultured cells |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04742504/registered